• PhysicsX

  Participated · Series C · Jun 2026

  PhysicsX offers an AI-based engineering platform that predicts physical behavior in seconds rather than hours or days, enabling engineers to test many more design variations. Its platform is used across aerospace and defense, semiconductors, industrial machinery, automotive, energy and materials. The company plans to expand its platform capabilities, develop larger pre-trained "Large Physics Models," and grow its geographic presence including the U.S. and a new office in Singapore. Recent financing will fund that expansion and product development. Financially, PhysicsX reported rapid commercial momentum: it doubled recognized revenue and tripled booked revenue in the past year while more than doubling its customer count. The company has grown its team to over 300 employees in the last 12 months.

• Fount

  Participated · Series A · Mar 2023

  Fount delivers individualized, n=1 experimentation combined with one-on-one coaching through its flagship Fount Pro service, targeting energy, focus, mood, sleep, gut health, longevity, fertility, and body composition. Coaches include former military special operators, Olympic sports scientists, and sleep researchers, and the company began its work with professional athletes and Navy SEALs before expanding to executives, entrepreneurs, and new parents. Fount combines proprietary data sets with AI expertise to build scalable, personalized products and in 2022 launched FlyKitt, a patented jet‑lag solution that the company says allows more than 90% of users to travel with minimal to no jet lag. The company announced plans to launch additional products for sleep and women’s health in 2023, with early results showing a reported 90% reduction in PMS symptoms for one product. Financially, Fount recently completed a $12M Series A fundraise to expand its Fount Pro service and support new product development. Fount is headquartered in Los Angeles, CA, and is led by founder and CEO Andrew Herr.

• Enveda Biosciences

  Participated · Series B · Dec 2022

  Enveda is a clinical-stage biotechnology company that learns from life’s chemistry to create small-molecule therapeutics using AI-powered metabolomics and a proprietary chemical sequencer. The platform makes previously inaccessible natural chemistry searchable and uses automation to map therapeutic properties at high throughput. Enveda says it delivers 12+ development candidates 4× faster and 10× cheaper than industry averages and has built one of the world’s largest collections of natural samples. Its pipeline includes sixteen preclinical programs, more than a dozen development candidates, four IND-enabling programs, and one clinical program. ENV-294, the lead program, is a first-in-class oral anti-inflammatory small molecule discovered on the platform and has moved into a Phase 1b trial after favorable Phase 1a results; Enveda has enrolled the first patient. The company recently raised additional capital and added industry veteran Dr. Mikael Dolsten to its board to support clinical advancement across atopic dermatitis, asthma, inflammatory bowel disease, obesity, and other indications. Enveda harnesses AI-powered tools to identify and characterize molecules produced by living organisms, building a database of chemical biodiversity it calls the library of life. Its platform integrates computational methods with deep chemical and biological insights to uncover novel mechanisms of action and drug candidates. The company has advanced ENV-294, a first-in-class molecule for atopic dermatitis and asthma, into clinical trials and highlights the potential for a safe, effective oral therapy in immunology and inflammation. Enveda plans to expand its clinical pipeline in 2025 and further enhance its AI-driven discovery capabilities. The company frames its approach as metabolite-driven drug development aimed at delivering medicines faster by learning from evolved solutions in nature. Enveda is a biotechnology company that uses an AI-powered platform combining metabolomics, machine learning, and automated high-throughput laboratory workflows to translate natural compounds into drug candidates. Its platform has characterized the structure and function of over 1 million natural compounds, creating the largest known natural product dataset custom-built for modern drug discovery. The company says this approach answers what molecules are and what they do at scale and enables discovery roughly four times faster than historical averages. Enveda’s pipeline includes 10 Development Candidates across immunology & inflammation, obesity, fibrosis, and neurosensory indications. The company recently received IND clearance for ENV-294, which entered Phase I at the end of October. The new funding will support multiple clinical catalysts in 2025 and 2026 and further investment in the platform and discovery programs. Enveda Biosciences, founded in 2019 and based in Boulder, Colorado, combines AI with ethnobotanical knowledge to identify medicinal molecules from plants. The company has assembled a database of about 38,000 medicinal plants linked to roughly 12,000 diseases and symptoms. Using a transformer model that deciphers the "chemical language" of whole samples, Enveda prioritizes sets of molecules for development rather than studying single compounds in isolation. That platform has produced near-term assets: two drugs (one for skin conditions including eczema, and one for inflammatory bowel diseases) are expected to enter clinical trials later this year. Financially, the company has raised capital that totals $230 million to date and plans to pursue a Series C after the start of those clinical trials. Enveda builds a proprietary platform that combines large language models, metabolomics, and robotics to create a high-resolution chemical map of nature and search nature’s chemical space for drug discovery. The platform addresses long-standing obstacles in natural product drug development, including active molecule identification, property and structure prioritization, amenability to medicinal chemistry, and large-scale material access. Enveda pairs this technology with experienced drug hunters and data scientists to advance platform-derived molecules. The company plans to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications. Financially, Enveda has been raising growth capital to advance its pipeline and platform and recently completed additional financing to support clinical progress. For more information, Enveda directs readers to envedabio.com.

• Octant

  Participated · Series B · Apr 2022

  Octant combines synthetic biology, high-throughput multiplexed assays, synthetic chemistry, and computation to build a platform for engineering and interrogating drugs, proteins, and cellular pathways at scale. The platform generates proprietary datasets that map relationships among drug candidates, genetics, biochemical mechanisms, and disease phenotypes to guide discovery of novel mechanisms of action. Octant will use Series B proceeds to expand platform capabilities and its pipeline, advance its proprietary drug discovery technology, and generate extensive datasets. The company plans to develop multiple additional therapeutic programs, including small molecule chaperone therapies for rare genetic diseases. Octant also announced a Deep Mutational Scanning collaboration with Bristol Myers Squibb to apply its DMS technologies to inflammation-related pathways. Senior hires and advisory appointments, including Rick Artis as Chief Scientific Officer and Feng Zhang to the Scientific Advisory Board, accompany the company’s growth. To date, Octant has raised $115 million in funding. Octant develops a polypharmacology discovery platform that uses synthetic biology, genome engineering, next-generation sequencing, functional genomics and computation to map activity across thousands of receptor pathways in human cells. The platform focuses initially on G-protein coupled receptors (GPCRs) and their downstream signaling to engineer multi-target drug leads for complex diseases such as metabolic and neurological disorders. Octant uses genetic barcodes to reveal chemical–receptor activity in pooled assays, increasing throughput and reducing costs versus serial discovery approaches. The company pursues internal development programs and strategic partnerships with pharmaceutical firms to advance candidates that are difficult to address with single-target approaches. Octant has also open-sourced part of its platform under the Open COVID Pledge and shared repurposing efforts and a SwabSeq protocol for the COVID-19 pandemic. The company is headquartered in Emeryville, Calif.

• Imprint

  Participated · Series A · Nov 2021

  Imprint is a New York-based financial technology company that partners with leading brands to design, issue, and operate co-branded credit products and loyalty experiences through its proprietary issuing and processing stack, ImprintCore. The platform gives brands end-to-end control of the customer journey—from application to spend, earn, redeem, and repeat—while supplying rich data and personalization capabilities. Imprint’s model has attracted partners such as Booking.com, Rakuten, Crate & Barrel, and Fetch, contributing to 200 % year-over-year growth in its cardholder base. Brands that switch to Imprint report 2× higher wallet share, a 20 % increase in spend, and an 8× lift in customer lifetime value versus legacy programs. The company also secured a AAA rating from Fitch for its inaugural $300 million securitization, underscoring strong capital-markets validation. With fresh capital, Imprint intends to strengthen its core platform, introduce debit, secured card, and flexible financing products, and build AI-driven automation alongside a brand-funded Imprint Rewards Network. Over the next three years it aims to evolve traditional co-brand cards into a comprehensive loyalty platform that delivers “premium access” for customers of top consumer brands.

No current team members are available.